-
Fils dominates Cobolli to book Cincinnati final
-
Coach Rennie hails clinical All Blacks after Springboks Test win
-
Spurs lacked fight in dismal defeat at Brentford says De Zerbi
-
Charlton deliver blow to 'under pressure' Hammers boss Nuno
-
Inter thrash Monza to launch Serie A title defence
-
Carrick keeps calm despite Man Utd misery, big-spending Spurs crushed
-
Shambolic Spurs battered by Brentford
-
Canada's Carney stands up to Trump, despite risks
-
Pogacar wins Vuelta a Espana opening stage
-
Lens hammer Auxerre thanks to Thauvin penalty double
-
Clinical New Zealand shock wasteful South Africa in first Test
-
No singles for Serena, but she joins Alcaraz for US Open
-
Canada hits back with new tariffs after trade talks with US fail
-
Joao Pedro extends Chelsea stay with new long-term deal
-
Swedish police identify 17-year-old girl as victim in school sword attack
-
Yamaguchi to face An in hunt for fourth badminton world crown
-
Carrick keeps calm despite Man Utd misery, Sage beaten in first game as Palace boss
-
Norris clinches pole for Dutch GP
-
France to deliver interceptor missiles to Ukraine after new Russian strikes
-
Norris clinches pole for Dutch Grand Prix
-
Serena Williams and Alcaraz unite in US Open mixed doubles
-
Pope Leo calls for courage in Rimini visit after stop in tiny San Marino
-
Macron pledges air defence as 13 killed in Russia, Ukraine strikes
-
Man Utd must learn from 'frustrating' defeat at Hull: Carrick
-
DR Congo capital wary of Ebola nightmare
-
Yamaguchi on course for fourth badminton world crown
-
Swedish police name 17-year-old girl as victim in school sword attack
-
Man Utd humiliated by Hull in dismal start to Premier League season
-
South Korea sends first container ship through Arctic route
-
Anthropic market debut could break SpaceX IPO record: media
-
Trescothick eager to keep England job despite Hussey approach
-
Pope's 'couturier of the sacred' fueled by faith
-
Indonesia deploys hundreds of soldiers to tackle Borneo fires
-
Duplantis locked in on 'grinding' for big bars
-
The last lap: Fans, drivers bid fond farewell to Dutch GP
-
Stokes says decision to leave Headingley off Ashes roster 'shambolic'
-
Silesia Diamond League: four events to watch
-
New arrival Rodri to miss Elche opener: Barca's Flick
-
Russell wins Dutch GP sprint race, Antonelli fourth
-
Atletico's Alvarez to return against Villarreal: Simeone
-
Mercedes driver George Russell wins Dutch GP sprint race
-
Dozens of civilians killed, kidnapped as jihadists clash in Nigeria
-
Ukraine strikes kill two children after Russia's deadly mall attack
-
Former envoys urge joint French, UK action on Palestinian territories
-
Pope visits San Marino, before addressing Italian political gathering
-
Australia lead by 101 in 2nd Bangladesh Test as 18 wickets fall on day one
-
Trump tariffs heap up as Canada tries to curb US reliance
-
'Aura' battles leap from social media to Latin America streets
-
Australia lose three wickets after skittling Bangladesh for 64
-
US, Canada fail to reach trade pact to avert Trump tariffs
Mesothelioma Hope Marks National Cancer Research Month With Latest Advances in Mesothelioma Treatment and Diagnostics
New data from the CheckMate 743 trial, FDA-approved immunotherapy combinations, and emerging therapies are offering renewed hope to mesothelioma patients and families.
CHESTNUT HILL, MA / ACCESS Newswire / May 26, 2026 / Mesothelioma Hope, a leading online resource providing education, patient advocacy, and support for those diagnosed with mesothelioma, is recognizing National Cancer Research Month this May by highlighting significant advances in mesothelioma research that are improving survival rates and quality of life for patients across the United States.
Approximately 3,000 people in the U.S. receive a mesothelioma diagnosis each year. Because this rare asbestos-caused cancer is often not detected until its later stages, advances in early detection, treatment, and clinical trial access are critically important.
This year's National Cancer Research Month theme, "United by Cancer Research," reflects a growing coalition of patients, caregivers, researchers, and advocates working together to accelerate progress. Mesothelioma Hope is proud to be part of that effort, tracking the latest developments and connecting patients with the resources they need.
Key Mesothelioma Research Milestones in 2026
Immunotherapy Extends Survival - Long-term follow-up data from the CheckMate 743 study showed that 14% of patients receiving nivolumab plus ipilimumab (Opdivo® + Yervoy®) were alive at 5 years, compared to 6% on chemotherapy alone. For patients with non-epithelioid mesothelioma, 5-year survival improved from approximately 1% to 12%, which is a landmark result.
FDA-Approved Combination Therapy - The KEYNOTE-483 trial demonstrated that pembrolizumab (Keytruda®) combined with chemotherapy shrank or controlled tumors in 62% of patients, following the FDA's approval of this regimen in 2024.
Emerging Treatments - CAR T-cell therapy, gene therapy, photodynamic therapy, and proton beam therapy are all showing promise in early-stage trials. As of May 2026, more than 50 mesothelioma clinical trials are actively recruiting patients.
Advanced Diagnostics - Cryobiopsy, liquid biopsy, and AI-assisted imaging analysis are helping doctors detect mesothelioma earlier and match patients to more targeted treatments.
"Things have improved somewhat, but not as much as I would like. That's why we continue to do research - to try and make the treatment better. The rate of research is accelerating substantially."
- Dr. Edward Levine, mesothelioma specialist, Atrium Health Wake Forest Baptist
How Mesothelioma Hope Supports Patients During National Cancer Research Month
In recognition of National Cancer Research Month, Mesothelioma Hope is encouraging patients and families to explore available clinical trials and connect with specialists to learn more about their treatment options.
Mesothelioma Hope's Patient Advocates are available 24/7 to help:
Connect patients with mesothelioma specialists and leading cancer centers
Find clinical trials that match a patient's diagnosis and treatment history
Provide free educational guides covering treatments, prognosis, and legal options
Facilitate access to support groups and financial assistance resources
A free 2026 Mesothelioma Guide is available at www.mesotheliomahope.com/mesothelioma-guide.
About Mesothelioma Hope
Mesothelioma Hope is a comprehensive patient support resource dedicated to helping individuals diagnosed with mesothelioma and their families access the information, specialists, and support they need. Through its team of Patient Advocates, the organization provides free guidance on treatment options, clinical trials, financial assistance, and legal resources. Mesothelioma Hope can be reached 24/7 by calling (866) 608-8933 or by visiting www.mesotheliomahope.com.
MEDIA CONTACT
Chris Carberg
(855) 346-6101
[email protected]
1330 Boylston St, Suite #400, Chestnut Hill, MA 02467
SOURCE: Mesothelioma Hope
View the original press release on ACCESS Newswire
N.Walker--AT